Theriva Biologics (TOVX) Revenue (2010 - 2026)

Theriva Biologics (TOVX) posted quarterly Revenue of $300000.0 for Q1 2026, up 130.86% quarter-over-quarter from -$972121.0 in Q4 2011.

Theriva Biologics (TOVX) Revenue (2010 - 2026) Analysis & Trends

Theriva Biologics (TOVX) has reported Revenue for 3 consecutive years, with $300000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Revenue changed N/A year-over-year to $300000.0; the TTM figure through Mar 2026 stood at -$23138.0 (changed N/A YoY), while the FY2010 annual figure was $2.6 million, changed N/A from the prior year.
Revenue advanced to $300000.0 in Q1 2026 per TOVX's latest filing, from -$972121.0 in the prior quarter.
Across five years, Revenue topped out at $300000.0 in Q1 2026 and bottomed at $300000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	1.52 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	145.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	1.71 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	1.29 Bn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	1.06 Bn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	425.49 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	674.14 Mn
10	Theriva Biologics	10.64 Mn	10.64 Mn	-	-

Download Data